Thanks Peace. Over 18 months ago PYC said there were interested parties concerning the CD40L program, you'd have to think a deal should be very close by now? Rheumatoid arthritis - multi-billion dollar target as we very well know.
With industry trending towards early-stage drug discovery deals and the CD40 ligand program being most advanced with fully optimized leads ready to go preclinical, this section highlighted below (old report) looks ever more appealing right now. The CD40L peptide leads should have a value of over $400m+ today. That's just one of their in-house programs. But yes, we are well overdue for some updates on this program :-)
Eight acquisitions of companies with biologics discovery libraries in less than 2 years. Average valuation at acquisition of A$450m. 62% of companies acquired at pre-clinical stage.
Taken from one of Galapagos' recent presentations...
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)